109 related articles for article (PubMed ID: 7686880)
1. COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma.
Liang R; Todd D; Chan TK; Chiu E; Lie A; Ho F
Hematol Oncol; 1993; 11(1):43-50. PubMed ID: 7686880
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
3. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
[TBL] [Abstract][Full Text] [Related]
4. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
[TBL] [Abstract][Full Text] [Related]
5. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
6. m-BACOD chemotherapy for intermediate- and high-grade non-Hodgkin's lymphoma.
Liang R; Chiu E; Chan TK; Todd D; Ho F
Cancer Chemother Pharmacol; 1991; 28(2):135-8. PubMed ID: 1711934
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
[TBL] [Abstract][Full Text] [Related]
8. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
9. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
10. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
[TBL] [Abstract][Full Text] [Related]
12. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. The Nebraska Lymphoma Study Group.
Vose JM; Anderson JR; Bierman PJ; Bast M; Weisenburger D; Chan WC; Bishop MR; Armitage JO
Semin Hematol; 1994 Apr; 31(2 Suppl 3):4-8. PubMed ID: 7521065
[No Abstract] [Full Text] [Related]
13. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K
Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085
[TBL] [Abstract][Full Text] [Related]
14. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
[TBL] [Abstract][Full Text] [Related]
15. Management of advanced stage intermediate grade non-Hodgkin's lymphomas.
Liang RH; Chiu EK; Chan TK; Todd D; Loke SL
Hematol Oncol; 1990; 8(3):147-54. PubMed ID: 1695608
[TBL] [Abstract][Full Text] [Related]
16. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
17. [COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
Niitsu N; Umeda M; Shirai T
Nihon Ronen Igakkai Zasshi; 1993 Sep; 30(9):753-8. PubMed ID: 7693992
[TBL] [Abstract][Full Text] [Related]
18. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
Niitsu N; Umeda M
Leukemia; 1998 Sep; 12(9):1457-60. PubMed ID: 9737696
[TBL] [Abstract][Full Text] [Related]
19. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
